Is there a role for intraperitoneal chemotherapy in early stage pelvic high-grade serous carcinoma?

Patients with Stage I/II pelvic high-grade serous carcinoma (HGSC) have significant risk of recurrence and death. Although previous studies demonstrate overall survival benefit with intraperitoneal chemotherapy (IP) in Stage III disease, no studies have evaluated the outcomes in early stage disease. We offered IP chemotherapy (IP/IV) to patients with Stage I/II HGSC from 2009−2022. The objectives was to evaluate recurrence and overall survival in this cohort of patients, compared to those who received standard intravenous (IV) chemotherapy.